(San Diego, Calif., February, 27 2018) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing platform for chimeric antigen receptor (CAR) T-cell agent evaluation with bioluminescent imaging capabilities.
CAR T-cell therapies are an exciting advent in the evolving field of immune-therapeutics. CAR T-cell agents utilize CAR T-cells that recognize tumor-associated antigens and subsequently promote tumor elimination. The remarkable efficacy of CAR T-cell compounds has led to hundreds of clinical trials with two notable successes recently approved by the FDA to treat refractory B-cell precursor acute lymphoblastic leukemia (ALL).
CrownBio, a leader in the field of preclinical immuno-oncology research, offers a CAR T-cell platform for proof-of-concept and therapeutic efficacy validation. Clinically relevant in vivo and in vitro models combine with a comprehensive suite of analytical services to enable efficient, early evaluation of CAR T-cell agents. The addition of bioluminescence imaging (BLI) for non-invasive evaluation of systemic and orthotopic tumor progression, in real-time, further enhances an already robust platform and provides a unique set of solutions to advance CAR T-cell therapies.
“We are committed to delivering innovative services to help our clients’ develop improved cancer therapeutics,” said Dr. Rajendra Kumari, CrownBio’s Chief Scientific Officer, UK. “Our non-invasive BLI capabilities, applied to CAR T-cell evaluation platform, deliver cutting-edge in vivo data that helps drug developers uncover insights to guide successful downstream development and clinical application of CAR T-cell agents.”
Learn more about CrownBio’s CAR T-cell evaluation platform at https://www.crownbio.com/oncology/immuno-oncology/car-t-cell-therapy-models/
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Scre...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
Indivumed Services GmbH, a Crown Bioscience company, has received laboratory accreditation from the College of American Pathologists (CAP), highlighting its commitment to excellence in laboratory s...
Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Crown Bioscience collaborates with HanX Biopharmaceutical, enabling the progression of HX009 to clinical trials for the treatment of lymphoma. The study demonstrates the efficacy of HX009 in target...
Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...